

Eisuke Murakami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7351639/publications.pdf>

Version: 2024-02-01

79
papers

1,165
citations

394286

19
h-index

477173

29
g-index

81
all docs

81
docs citations

81
times ranked

1747
citing authors

#	ARTICLE	IF	CITATIONS
1	Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. <i>Journal of Medical Virology</i> , 2015, 87, 1913-1920.	2.5	73
2	Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. <i>Hepatology Research</i> , 2016, 46, 758-764.	1.8	60
3	Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2019, 97, 75-81.	0.9	44
4	Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 348-355.	2.0	43
5	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2015, 45, 656-662.	1.8	42
6	Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820.	1.8	41
7	Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. <i>Journal of Gastroenterology</i> , 2019, 54, 291-296.	2.3	39
8	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517.	0.9	38
9	Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00179.	1.3	37
10	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222.	0.9	33
11	Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. <i>Journal of Hepatology</i> , 2015, 63, 554-563.	1.8	29
12	Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. <i>Cancers</i> , 2021, 13, 3958.	1.7	29
13	Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1780-1786.	1.4	28
14	Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay. <i>PLoS ONE</i> , 2015, 10, e0130022.	1.1	28
15	Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon- α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. <i>Hepatology Research</i> , 2012, 42, 442-453.	1.8	27
16	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2020, 9, 148-155.	4.2	27
17	Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. <i>Hepatology Research</i> , 2020, 50, 885-888.	1.8	27
18	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797.	0.9	26

#	ARTICLE	IF	CITATIONS
19	Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 215.	3.5	23
20	Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes. <i>Virology</i> , 2018, 525, 48-61.	1.1	20
21	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. <i>Liver Cancer</i> , 2021, 10, 151-160.	4.2	20
22	Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma. <i>European Radiology</i> , 2015, 25, 3272-3281.	2.3	19
23	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. <i>Journal of Infection</i> , 2016, 72, 91-102.	1.7	17
24	Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. <i>BMC Cancer</i> , 2018, 18, 633.	1.1	17
25	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306.	0.8	17
26	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	0.6	17
27	Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2105-2112.	1.4	16
28	Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 193-204.	1.8	16
29	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 217-226.	2.3	16
30	Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 867-872.	0.4	16
31	Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology Research</i> , 2020, 50, 1234-1243.	1.8	15
32	Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. <i>BMC Gastroenterology</i> , 2019, 19, 169.	0.8	14
33	Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828.	1.2	14
34	A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 283-287.	0.4	14
35	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	1.8	13
36	Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. <i>Scientific Reports</i> , 2019, 9, 12101.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. <i>Hepatology Research</i> , 2020, 50, 1222-1233.	1.8	13
38	Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2018, 90, 1834-1840.	2.5	12
39	Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS. <i>Scientific Reports</i> , 2017, 7, 10146.	1.6	11
40	Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092205.	1.4	11
41	Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1412-1419.	1.4	10
42	Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1. <i>Journal of Infectious Diseases</i> , 2020, 222, 2061-2070.	1.9	10
43	Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study. <i>Antiviral Therapy</i> , 2018, 23, 639-646.	0.6	9
44	The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2017, 23, 239-248.	0.6	8
45	Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. <i>BMC Gastroenterology</i> , 2020, 20, 314.	0.8	8
46	Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2020, 98, 727-733.	0.9	8
47	Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab. <i>Medicine (United States)</i> , 2021, 100, e27576.	0.4	8
48	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 320.	1.7	8
49	<sc>CTL</sc>-associated and <sc>NK</sc> cell-associated immune responses induce different <sc>HBV DNA</sc> reduction patterns in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1555-1564.	1.0	6
50	Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 341-346.	0.4	6
51	Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice. <i>Journal of Gastroenterology</i> , 2019, 54, 650-659.	2.3	6
52	Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. <i>Journal of General Virology</i> , 2019, 100, 1123-1131.	1.3	6
53	Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. <i>Journal of Medical Virology</i> , 2020, 92, 210-218.	2.5	5
54	Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution. <i>Journal of Gastroenterology</i> , 2020, 55, 877-887.	2.3	5

#	ARTICLE	IF	CITATIONS
55	Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1685-1693.	1.4	5
56	Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. <i>Oncology</i> , 2021, 99, 327-335.	0.9	5
57	<i>In vitro</i> analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. <i>Molecular Medicine Reports</i> , 2020, 23, .	1.1	5
58	Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 592-599.	1.4	5
59	The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment. <i>PLoS ONE</i> , 2022, 17, e0262675.	1.1	4
60	Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 267-270.	0.4	3
61	Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. <i>Internal Medicine</i> , 2020, 59, 941-944.	0.3	3
62	A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 839-843.	0.4	3
63	Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients. <i>Journal of Infection</i> , 2022, 84, 391-399.	1.7	3
64	Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 421-427.	0.4	2
65	The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 443-450.	0.6	2
66	Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection—Pilot study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 400-409.	1.0	1
67	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 491-498.	0.9	1
68	Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. <i>Internal Medicine</i> , 2021, 60, 2047-2053.	0.3	1
69	A case of primary hepatic leiomyosarcoma. <i>Acta Hepatologica Japonica</i> , 2019, 60, 358-365.	0.0	1
70	Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL. <i>Journal of Infectious Diseases</i> , 2023, 227, 686-695.	1.9	1
71	Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the <i>ATP8B1</i> Gene. <i>Case Reports in Gastroenterology</i> , 2022, 16, 110-115.	0.3	1
72	Multicentric hepatocarcinogenesis at 6 and 13 years after sustained viral response to hepatitis C virus. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 204-209.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Reply from the authors. <i>Hepatology Research</i> , 2020, 50, 1393-1393.	1.8	0
74	A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system. <i>IDCases</i> , 2021, 23, e01059.	0.4	0
75	A case of successful repeated lusutrombopag administration for thrombocytopenia in a patient with cirrhosis requiring multiple invasive procedures. <i>Acta Hepatologica Japonica</i> , 2021, 62, 136-143.	0.0	0
76	A case of simultaneous hepatocellular carcinoma and cholangiocellular carcinoma in a patient with alcoholic liver injury. <i>Acta Hepatologica Japonica</i> , 2021, 62, 300-309.	0.0	0
77	Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 559, 78-83.	1.0	0
78	A patient with chronic hepatitis B who developed hepatocellular carcinoma with hypervascularity in 9 years of close follow-up. <i>Acta Hepatologica Japonica</i> , 2022, 63, 24-34.	0.0	0
79	A patient with polycystic liver disease combined with portal hypertension that died due to bacterial peritonitis as a secondary cause of death. <i>Acta Hepatologica Japonica</i> , 2022, 63, 279-285.	0.0	0